1 – 17 of 17
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study
(
- Contribution to journal › Article
- 2018
-
Mark
Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma : A critical assessment of the R-IPI, IPI, and NCCN-IPI
(
- Contribution to journal › Article
-
Mark
Proteomic Profiling of Diffuse Large B-Cell Lymphomas
(
- Contribution to journal › Article
- 2016
-
Mark
Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms
2016)(
- Thesis › Doctoral thesis (compilation)
-
Mark
Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma : a Swedish Lymphoma Registry study
(
- Contribution to journal › Article
- 2015
-
Mark
F-18-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study
(
- Contribution to journal › Article
- 2014
-
Mark
Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study
(
- Contribution to journal › Article
- 2013
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
(
- Contribution to journal › Article
- 2012
-
Mark
Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
(
- Contribution to journal › Article
- 2010
-
Mark
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
(
- Contribution to journal › Article
- 2009
-
Mark
Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas
(
- Contribution to journal › Article
-
Mark
Highly increased familial risks for specific lymphoma subtypes
(
- Contribution to journal › Article
-
Mark
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
(
- Contribution to journal › Article
- 2007
-
Mark
Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Diffuse large B-cell lymphoma - tumour characteristics on RNA and protein level associated with prognosis
2007)(
- Thesis › Doctoral thesis (compilation)
- 2004
-
Mark
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study.
(
- Contribution to journal › Article